Charles W Newhall Iii Supernus Pharmaceuticals, Inc. (SUPN) insider trading activity

Charles W Newhall Iii is Director of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 119,644 shares of SUPN, which is worth approximately $5.38 Million. The most recent transaction as insider was on Nov 21, 2025, when has been sold 15,000 shares (Common Stock) at a price of $12.98 per share, resulting in proceeds of $194,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 120K

14.33% 3M change

8.16% 12M change

Total Value Held $5.38 Million

CHARLES W NEWHALL III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 21 2025	BUY Exercise of conversion of derivative security	$194,700 $12.98 p/Share	15,000 Added 11.14%	119,644 Common Stock
Oct 09 2025	SELL Open market or private sale	$1,278,500 $51.14 p/Share	25,000 Reduced 19.28%	104,644 Common Stock
Aug 27 2025	SELL Open market or private sale	$161,495 $45.01 p/Share	3,588 Reduced 2.69%	129,644 Common Stock
Aug 25 2025	SELL Open market or private sale	$45,000 $45.0 p/Share	1,000 Reduced 0.74%	133,232 Common Stock
Aug 22 2025	SELL Open market or private sale	$63,540 $45.0 p/Share	1,412 Reduced 1.04%	134,232 Common Stock
Feb 22 2025	BUY Grant, award, or other acquisition	-	5,369 Added 3.81%	135,644 Common Stock
Nov 11 2024	SELL Open market or private sale	$387,768 $36.24 p/Share	10,700 Reduced 7.59%	130,275 Common Stock

Nov 11 2024	BUY Exercise of conversion of derivative security	$182,600 $9.13 p/Share	20,000 Added 12.42%	140,975 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	3,886 Added 3.11%	120,975 Common Stock
Nov 16 2023	SELL Open market or private sale	$70,025 $28.01 p/Share	2,500 Reduced 2.09%	117,089 Common Stock
Nov 16 2023	BUY Exercise of conversion of derivative security	$68,902 $9.24 p/Share	7,457 Added 5.87%	119,589 Common Stock
Feb 22 2023	BUY Grant, award, or other acquisition	-	3,882 Added 3.35%	112,132 Common Stock
Dec 28 2022	BUY Exercise of conversion of derivative security	$68,903 $7.9 p/Share	8,722 Added 7.32%	110,453 Common Stock
Feb 19 2022	BUY Grant, award, or other acquisition	-	4,222 Added 3.98%	101,731 Common Stock

CWN

Charles W Newhall Iii

Director

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Value

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

Operation

Value

Type

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN

Account